Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 41Radiotherapy 38Cisplatin 35Oxaliplatin 32Leucovorin 24Paclitaxel 22Irinotecan 20Docetaxel 17Neoadjuvant Therapy 14Carboplatin 13Radiation 12Capecitabine 12Surgical Procedures, Operative 10Cetuximab 8Biopsy 8durvalumab 7Gefitinib 7Chemotherapy, Adjuvant 7tremelimumab 6pembrolizumab 6Nivolumab 6Magnetic Resonance Spectroscopy 6Folfox protocol 6Taxes 5Immunohistochemistry 5Endoscopy 5Gene Expression Profiling 4Epirubicin 4Drug Therapy 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma Of Esophagus × LY2940680 × Clear all
NCT02530437 2023-07-10

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
7 enrolled 11 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡